Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.
Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors First patient dosed in IDE397 combination with taxane ...
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics ...
(ORLANDO, Dec. 9, 2025) Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback